Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03652961 · ClinicalTrials.gov registry record · Phase 4
Rheumatoid Arthritis Memory B Cells and Abatacept
A Phase 4 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
NCT03652961 is a Phase 4 study that has completed, run by NYU Langone Health. The registered enrollment target is 25 participants.
The verdict
NCT03652961, a Phase 4 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
Study Summary
Single-Open Label Study to Assess Changes in the Immune Profile in Response to Treatment with Intravenous Abatacept Adults with Rheumatoid Arthritis who are Naive to Biologic Disease-Modifying Antirheumatic Drugs
Interventions
- DRUG Abatacept
- DRUG DMARDs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2019-06-02 |
| Est. Completion | 2021-09-27 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03652961
The ClinicalTrials.gov registry entry for NCT03652961 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Abatacept is the first listed.
NCT03652961 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03652961 about?
NCT03652961 is a clinical study titled "Rheumatoid Arthritis Memory B Cells and Abatacept". Single-Open Label Study to Assess Changes in the Immune Profile in Response to Treatment with Intravenous Abatacept Adults with Rheumatoid Arthritis who are Naive to Biologic Disease-Modifying Antirheumatic Drugs
What is the current status of trial NCT03652961?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2019-06-02. Estimated completion is 2021-09-27.
What interventions are being tested in trial NCT03652961?
The interventions under investigation include: Abatacept (DRUG), DMARDs (DRUG).
Who is sponsoring clinical trial NCT03652961?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.